• Fluorescein TSA Fluorescence System Kit: Amplified Detection

  2026-06-02

  Detect elusive biomolecules with the Fluorescein TSA Fluorescence System Kit, engineered for ultrasensitive signal amplification in fixed tissue and cell assays. This kit’s optimized HRP-catalyzed tyramide deposition outperforms conventional fluorescence protocols, unlocking vivid visualization of low-abundance targets even in complex models of disease.

• DiscoveryProbe™ Metabolism-related Compound Library: Technic

  2026-06-02

  The DiscoveryProbe™ Metabolism-related Compound Library provides a rigorously validated set of 493 small molecules for targeted metabolism research, facilitating enzyme inhibition assays and pathway modulation in vitro or ex vivo. This library is optimized for reproducibility and high-throughput workflows but is not suitable for clinical or diagnostic applications. Researchers should use this toolset for mechanistic studies rather than translational or in vivo work.

• Dissecting Drug Responses: Improved In Vitro Metrics in Canc

  2026-06-01

  Schwartz's dissertation advances in vitro evaluation of anti-cancer drugs by distinguishing cell proliferation arrest from cell death, rather than relying on traditional amalgamated viability measures. This nuanced approach enables more precise characterization of drug efficacy, supporting improved experimental design and interpretation in cancer pharmacology.

• FITC Goat Anti-Mouse IgG (H+L) Antibody: Technical Applicati

  2026-06-01

  The FITC Goat Anti-Mouse IgG (H+L) Antibody provides a practical solution for sensitive and specific fluorescent detection of mouse IgG in immunofluorescence and flow cytometry workflows. It should be used exclusively with mouse primary antibodies in fluorescence-based applications and is not suitable for non-mouse targets or non-fluorescent detection methods.

• 3-Deazaneplanocin (DZNep): Precision Epigenetic Modulation i

  2026-05-31

  Explore the in-depth molecular mechanisms and advanced assay strategies for 3-Deazaneplanocin (DZNep), a leading epigenetic modulator in cancer research. This article offers unique insights into DZNep's role in apoptosis induction and cancer stem cell targeting, distinguishing it from existing resources.

• VE-822 ATR Inhibitor: Redefining Radiosensitization in PDAC

  2026-05-30

  This thought-leadership article explores the mechanistic and translational significance of the potent ATR inhibitor VE-822 (APExBIO) in overcoming radioresistance in pancreatic ductal adenocarcinoma (PDAC). Integrating new data from comparative radiosensitizer studies and multi-dimensional culture models, the piece provides actionable strategic guidance for researchers aiming to bridge preclinical insight and clinical impact in cancer chemoradiotherapy.

• ICG001: Precision Wnt/β-Catenin Modulation in Fibrosis Model

  2026-05-29

  Explore how ICG001, a potent Wnt/β-catenin pathway inhibitor, enables refined dissection of fibrotic mechanisms and experimental design in liver and pulmonary fibrosis. This article delivers deep insight into assay decisions and translational research impact, advancing beyond standard protocols.

• Clozapine N-oxide (CNO): Chemogenetic Actuator for Neuroscie

  2026-05-29

  Clozapine N-oxide (CNO) is a biologically inert metabolite of clozapine used extensively as a chemogenetic actuator in neuroscience. It enables precise, non-invasive modulation of neuronal activity through DREADDs technology, with high solubility in DMSO and validated selectivity in rodent models.

• Acetylcholine Chloride: Catalyzing Gut-Brain Research Fronti

  2026-05-28

  Explore how Acetylcholine Chloride is revolutionizing translational neuroscience by enabling precise dissection of the gut-brain cholinergic axis, with a focus on the mechanistic underpinnings and strategic imperatives for researchers targeting pediatric epilepsy and beyond.

• Sulfaphenazole: Redefining Vascular Research via CYP2C9 Inhi

  2026-05-28

  Discover how Sulfaphenazole, a potent CYP2C9 inhibitor, advances vascular research and oxidative stress reduction through unique mechanistic insights. This article uniquely explores therapeutic and experimental protocols, setting it apart from existing resources.

• MK-1775 and the Future of G2 Checkpoint Abrogation in Cancer

  2026-05-27

  Explore the mechanistic and translational value of MK-1775 (Wee1 kinase inhibitor) in overcoming the G2 DNA damage checkpoint, with actionable guidance for researchers seeking to sensitize p53-deficient tumor cells to DNA-damaging agents. This article integrates the latest in vitro evaluation methodologies, competitive landscape insights, and strategic recommendations, while leveraging key findings from recent systems biology and translational research.

• KPT330 Enhances CRISPR-Cas9 Specificity via mRNA Export Cont

  2026-05-27

  The referenced study identifies KPT330, a selective nuclear export inhibitor, as a novel modulator that enhances the specificity of CRISPR-Cas9 genome and base editing by indirectly regulating Cas9 mRNA export. This approach represents a significant advance for reducing off-target effects in genome engineering and informs strategies for high-fidelity editing in mammalian cells.

• 3-Bromopyruvate and Cetuximab: Inducing Ferroptosis to Overc

  2026-05-26

  The referenced study demonstrates that combining 3-bromopyruvate with cetuximab effectively overcomes drug resistance in colorectal cancer cells through autophagy-dependent ferroptosis and apoptosis. This mechanistic breakthrough highlights the therapeutic potential of targeting multiple programmed cell death pathways to address cetuximab resistance.

• Deferoxamine Mesylate: Advanced Insights into Iron-Chelation

  2026-05-26

  Explore Deferoxamine mesylate as an iron-chelating agent with unique capabilities in ferroptosis regulation, oxidative stress protection, and HIF-1α stabilization. This article delivers deep scientific context and practical assay strategies, distinguishing itself with advanced mechanistic analysis and translational outlook.

• Cisplatin (CDDP): Optimizing Cancer Research Workflows

  2026-05-25

  Cisplatin (CDDP) remains the benchmark for modeling DNA crosslinking, apoptosis, and chemotherapy resistance in both in vitro and in vivo cancer research. This article delivers actionable protocols, troubleshooting insights, and leverages the latest advances—such as TAK1-YAP axis targeting in gastric cancer stem cells—to empower robust, reproducible oncology studies.

461 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page